Summary In order to understand in more detail the mechanism underlying the preferential hypoxic cytotoxicity of the benzotriazine N-oxide SR 4233, we have compared the hypoxic cytotoxicity of this drug to the rates of hypoxic metabolism in both DNA double strand break repair-competent and repair-deficient cell cultures. Rodent SCCVII cells and repair deficient, radiation sensitive cells (rodent XR-1, V-3, and human AT5BI) were most sensitive to SR 4233 under hypoxia with a lethal dose needed to kill 50% of cells (LDm0) 
HT 1080 cells (LD50 = 33 giM). The sensitivities to SR 4233 were found to be inversely proportional to the rates of SR 4233 metabolism in repair-competent cells (R2 = 0.9). However, XR-1 and V-3 cells were more sensitive to SR 4233 than predicted by the metabolism rate. Thus, the toxicity by SR 4233 towards hypoxic cells appears to result from two mechanisms; the rate of drug metabolism and the ability to repair DNA double strand breaks.
Solid tumours contain viable hypoxic cells which are resistant to killing by both radiation and chemotherapeutic drugs (Tannock & Guttman, 1981 ; Thomlinson & Gray, 1955) . One strategy to overcome this problem of hypoxic cells in solid tumours would be to combine traditional cancer therapy regimens with the use of agents that are preferentially toxic to hypoxic cells. SR 4233, a benzotriazine di-N-oxide, is currently being evaluated as a bioreductive cytotoxin to specifically kill hypoxic cells (Figure 1) . The drug has a high selective toxicity for hypoxic cells in vitro (Zeman et al., 1986) and is effective as an antitumour agent in vivo when combined either with radiation Brown & Lemmon, 1990) or with an agent which specifically induces tumour hypoxia (Brown 1987 ; Sun & Brown, 1989) . SR 4233 is reduced in hypoxic cells to form the two-and four-electron reduction products, SR 4317 and SR 4330, as measured by HPLC (Baker et al., 1988; Laderoute & Rauth, 1986; Walton et al., 1989) . Both of these products are nontoxic to cells under hypoxic or aerobic conditions (Baker et al., 1988; Zeman et al., 1986) . We have proposed that SR 4233 is reduced via a single-electron reduction pathway to form a free radical intermediate, the structure of which has been recently confirmed by ESR (Lloyd & Mason, personal communication) . Under aerobic conditions, the radical reacts with oxygen in a futile one-electron reduction cycle, generating superoxide in the process (Laderoute et al., 1988) . In the absence of oxygen, the SR 4233 radical may abstract hydrogen from DNA and other macromolecules, forming strand breaks which ultimately result in cell death. The major enzyme responsible for the bioreduction of SR 4233 appears to be P-450, both in liver microsomes (Walton et al., 1989) , and in human tumour cells (Wang et al., in preparation) .
Recent studies indicate that mammalian cell lines display marked variations in the hypoxic cytotoxicities to SR 4233 (Brown & Kuruppu, unpublished (Hirst et al., 1983) . CHO V-3 cells (Whitmore et al., 1989) were obtained courtesy of G.F. Whitmore, U. of Toronto. XR-1, a cell cycle specific gammaray sensitive CHO cell mutant (Stamato et al., 1983) (Figure 7b ). The cell lines SCCVII and AT5BI displaying the highest sensitivity to SR 4233 under hypoxia also metabolised the drug to the greatest extent. However, the rodent V-3 and XR-1 cells, which are deficient in repair of double strand breaks, were more sensitive to killing by SR 4233 under hypoxia than could be accounted for by their rates of drug metabolism.
Discussion
The results shown here demonstrate that rodent and human cells are preferentially susceptible to killing by SR 4233 under SR 4233 is a result of differing concentrations of these enzymes. Interestingly, hypoxic metabolism did not predict the aerobic sensitivities of cells to SR 4233. It is possible that the production of superoxide radicals during the metabolism of SR 4233 in air may be responsible for the aerobic toxicity. Thus, the toxicity of SR 4233 in air may be dependent not only on the amount of reductive enzyme, but also on the concentrations of oxygen radical scavengers or perhaps catalase or GSH-associated enzymes present in these cells.
This correlation of drug sensitivity under hypoxia with the rate of drug metabolism did not hold for the two CHO mutants, XR-1 and V-3, which are sensitive to ionising radiation due to a deficiency in DNA double strand break rejoining (Stamato et al., 1983; Whitmore et al., 1989) . Complementation studies showed that both these cell lines represent separate DNA repair deficient mutants. XR-1 and V-3 were found to be more sensitive to SR 4233 under hypoxia than predicted by their metabolism rate.
We conclude that the toxicity by SR 4233 in cells appears to result from two mechanisms; first, the rate of drug metabolism in individual cell lines, and second, the ability of cells to repair DNA double strand breaks produced by the drug. This suggests that the primary mechanism of hypoxic cell killing by SR 4233 is by the production of DNA double strand breaks. It should be noted, however, that the human fibroblastic cell line AT5BI, despite being X-ray sensitive, was not more sensitive to SR 4233 killing under hypoxia than predicted from its rate of metabolism of SR 4233. This may be related to the fact that AT cells have not shown a gross defect in DNA double strand break rejoining, although they do show reduced rejoining of chromosome breaks compared to normal cells (Cornforth & Bedford, 1985) , and lack the ability to repair poterftially lethal damage as judged by delayed plating experiments (Biedermann & Brown, 1989) . This lack of correlation between X-ray and SR4233 sensitivity is also seen in the data of Keohane et al. (1990) . These investigators showed that irs cells, which are radiationsensitive, but not deficient in the repair of DNA double strand breaks (Jones et al., 1990) , display similar hypoxic cytotoxicities by SR 4233 to the parental V79 vells. It would therefore appear that radiation sensitivity per se in the absence of a defect in double strand break rejoining is not a sufficient condition for sensitivity to SR 4233. This points to a possible difference in the mechanism of cell killing by radiation and SR 4233.
An important application of the present data is that it should allow a rapid means of predicting the sensitivity of individual human tumours to SR 4233 should this drug become used in the clinic. It would be relatively easy to characterise the likely drug sensitivity of such tumours by a measurement of the rate of metabolism of SR 4233 under hypoxia in a suspension or homogenate of the tumour cells. High rates of drug metabolism would indicate high drug sensitivity and the greater likelihood of tumour cell kill.
